Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sana Biotechnology stock

Own Sana Biotechnology stock in just a few minutes.

Sana Biotechnology, a company that develops platforms to replace or repair cells in our bodies, wrapped an upsized IPO at $588 million.

Morgan Stanley, Goldman Sachs Group, JPMorgan and BofA Securities were the bookrunners for the deal.

How to buy shares in Sana Biotechnology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SANA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Sana Biotechnology share price

Use our graph to track the performance of SANA stocks over time.

Sana Biotechnology shares at a glance

Information last updated 2021-04-21.
52-week range$21.21 - $44.60
50-day moving average $29.01
200-day moving average $31.58
Wall St. target price$41.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Sana Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sana Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sana Biotechnology financials

Gross profit TTM $0
Return on assets TTM -25.47%
Return on equity TTM -80.76%
Profit margin 0%
Book value N/A
Market capitalisation $4.4 billion

TTM: trailing 12 months

Shorting Sana Biotechnology shares

There are currently 2.6 million Sana Biotechnology shares held short by investors – that's known as Sana Biotechnology's "short interest". This figure is 163.1% up from 981,523 last month.

There are a few different ways that this level of interest in shorting Sana Biotechnology shares can be evaluated.

Sana Biotechnology's "short interest ratio" (SIR)

Sana Biotechnology's "short interest ratio" (SIR) is the quantity of Sana Biotechnology shares currently shorted divided by the average quantity of Sana Biotechnology shares traded daily (recently around 629885.85365854). Sana Biotechnology's SIR currently stands at 4.1. In other words for every 100,000 Sana Biotechnology shares traded daily on the market, roughly 4100 shares are currently held short.

To gain some more context, you can compare Sana Biotechnology's short interest ratio against those of similar companies.

However Sana Biotechnology's short interest can also be evaluated against the total number of Sana Biotechnology shares, or, against the total number of tradable Sana Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sana Biotechnology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Sana Biotechnology shares in existence, roughly 10 shares are currently held short) or 0.0301% of the tradable shares (for every 100,000 tradable Sana Biotechnology shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sana Biotechnology.

Find out more about how you can short Sana Biotechnology stock.

Sana Biotechnology share dividends

We're not expecting Sana Biotechnology to pay a dividend over the next 12 months.

Sana Biotechnology overview

Sana Biotechnology, Inc. , a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc.

Frequently asked questions

What percentage of Sana Biotechnology is owned by insiders or institutions?
Currently 12.12% of Sana Biotechnology shares are held by insiders and 8.512% by institutions.
How many people work for Sana Biotechnology?
Latest data suggests 263 work at Sana Biotechnology.
When does the fiscal year end for Sana Biotechnology?
Sana Biotechnology's fiscal year ends in December.
Where is Sana Biotechnology based?
Sana Biotechnology's address is: 188 East Blaine Street, Seattle, WA, United States, 98020

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site